Acq of Oxxon Therapeutics

Oxford Biomedica PLC
12 March 2007



For Immediate Release                                              12 MARCH 2007



                 Oxford BioMedica to acquire oxxon therapeutics

  Acquisition adds melanoma cancer vaccine and extends immunotherapy platform


Oxford, UK - 12 March 2007: Oxford BioMedica (LSE: OXB, 'Oxford BioMedica'), the
leading gene therapy company, announced today that it has entered into an
agreement to acquire Oxxon Therapeutics Limited ('Oxxon'), a privately held
biotechnology company, based in Oxford, UK. Oxxon is focused on the development
of novel therapeutic vaccines for the treatment of cancer and infectious
diseases.


Key aspects of the acquisition are:


   • Oxxon's lead cancer vaccine has completed a Phase II trial in melanoma,
    the only solid tumour that cannot be treated with Oxford BioMedica's TroVax;
   • Oxxon's technology has broad product applications in cancer and
    infectious diseases and will create new licensing opportunities;
   • Transaction value of £16 million will be satisfied by the issue of
    Oxford BioMedica shares; and
   • Assets acquired include net cash of approximately £3 million.


The acquisition of Oxxon provides Oxford BioMedica with a complementary cancer
immunotherapy product candidate. The product, Hi-8(R) MEL, has successfully
completed a Phase II trial for the treatment of advanced melanoma. Oxxon has
other therapeutic programmes addressing infectious diseases, including hepatitis
B and HIV. In addition, Oxxon has a strong intellectual property estate that
broadens and complements Oxford BioMedica's proprietary position in
immunotherapy and gene-based medicines.


Professor Alan Kingsman, Chief Executive of Oxford BioMedica, commented, 'We are
very pleased to have been able to take this opportunity to acquire of Oxxon
Therapeutics. The acquisition expands our immunotherapy pipeline and strengthens
our intellectual property position in the field of immunology. Oxxon's Hi-8(R)
MEL vaccine has generated encouraging Phase II results as a treatment of
advanced melanoma. The market opportunity for an effective melanoma vaccine is
substantial and this is a cancer type where our immunotherapy, TroVax, cannot be
developed because, unlike the vast majority of human tumours, melanomas do not
have 5T4 on the surface of the tumour cells. This acquisition is part of the
implementation of a plan for the development of our pipeline following
finalisation of a licensing deal for TroVax.'

Iain Wilcock, Deputy Managing Director of Quester, a major investor in Oxxon,
commented, 'We are very pleased with this transaction, which combines the broad
immunotherapy technology of Oxxon with one of the world's leading companies in
cancer vaccines and gene therapy. There is clear synergy in this combination
and, given Oxford BioMedica's technical and development expertise, we believe
that the enlarged company can maximise the opportunity for Oxxon's technology.'


Transaction details


The transaction is valued at £16 million, to be satisfied by the issue
27,551,628 Oxford BioMedica shares to Oxxon shareholders for the entire share
capital of Oxxon and 4,219,618 shares for the repayment of a loan from Oxxon
shareholders to Oxxon. The number of shares to be issued has been determined by
a reference price of 50.36p per share, being the average closing price of Oxford
BioMedica shares over the 30 days to 8 March 2007.


Oxxon's key investors, who as a result of the transaction will have an interest
in Oxford BioMedica shares, are the venture capital firms Quester, MVM Life
Science Partners and US-based East Hill Management.


25,814,138 of the issued shares will be subject to a lock up agreement for six
months followed by a period of orderly disposal through Oxford BioMedica's
corporate brokers. For the year ended 31 May 2006, Oxxon generated a loss before
tax of £3.9 million. Oxxon's gross assets at 31 May 2006 were £3.84 million.


Application will be made to the United Kingdom Listing Authority ('UKLA') for
the newly issued ordinary shares in Oxford BioMedica to be admitted to the
Official List of the UKLA and to the London Stock Exchange plc for admission to
trading on its market for listed securities ('Admission'). Under the terms of
the UKLA listing rules the acquisition is a Class 2 transaction, which does not
require shareholder approval. The transaction is conditional upon Admission.
Subject only to Admission the shares are expected to commence trading on 15
March 2007



-Ends-

For further information, please contact:

Oxford BioMedica plc:                                  Tel: [phone]
Professor Alan Kingsman, Chief Executive

Rothschild                                             Tel: [phone]
Dr Lynn Drummond

City/Financial Enquiries:                              Tel: [phone]
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan
Communications

Scientific/Trade Press Enquiries:                      Tel: [phone]
Gemma Price/ Holly Griffiths/ Katja Stout
Northbank Communications


N M Rothschild & Sons Limited, which is authorised and regulated by the
Financial Services Authority in the United Kingdom, is acting for Oxford
BioMedica and no one else in relation to the transaction and will not be
responsible to anyone other than Oxford BioMedica for providing the protections
afforded to clients of N M Rothschild & Sons Limited nor for providing advice in
relation to the proposed transaction.


Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on oncology and
neurotherapy. The Company was established in 1995 as a spin out from Oxford
University, and is listed on the London Stock Exchange.


Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes two clinical candidates and a preclinical targeted antibody therapy,
which is being developed in collaboration with Wyeth. The Company has started
Phase III development of its lead cancer immunotherapy product, TroVax, in renal
cancer and has an ongoing Phase II programme in various cancer settings
including renal, colorectal and prostate cancer. In neurotherapy, the Company's
lead product, ProSavin, is expected to enter clinical trials in Parkinson's
disease in 2007. The preclinical pipeline includes gene-based products for
vision loss, motor neuron disease and nerve repair.


The Company is underpinned by over 80 patent families, which represent one of
the broadest patent estates in the field. The Company has a staff of 72 split
between its main facilities in Oxford and its wholly owned subsidiary, BioMedica
Inc, in San Diego, California. Oxford BioMedica has corporate collaborations
with Wyeth, Intervet, Sigma-Aldrich, Viragen, MolMed and VIRxSYS; and has
licensed technology to a number of companies including Merck & Co, Biogen Idec,
GlaxoSmithKline and Pfizer.


Further information is available at www.oxfordbiomedica.co.uk


2. Oxxon Therapeutics

Oxxon Therapeutics is a private UK-based company developing innovative,
antigen-specific immunotherapies to treat patients with cancer and chronic
infectious diseases. The company's product pipeline is based on its proprietary
Hi-8(R) PrimeBoost immunotherapy platform, which is designed to stimulate potent
cellular immune responses. Oxxon has successfully completed a Phase II trial in
melanoma and has products candidates for the treatment of hepatitis B and HIV.


Oxxon's Hi-8(R) PrimeBoost therapy is a two-step approach whereby a 'prime'
vector encoding a disease-specific antigen(s) stimulates the immune system to
produce disease-specific T cells and is followed by a 'boost' containing the
same antigen(s) delivered in a non-replicating viral vector. The boost amplifies
the disease-specific T cells and creates a significant population of memory T
cells to target and eliminate diseased cells. The company and its collaborators
have demonstrated in published preclinical and human clinical studies that this
approach yields extremely potent T cell responses against the disease antigens
encoded in the Hi-8(R) PrimeBoost treatment as well as clinical benefit for
patients. In addition, Hi-8(R) PrimeBoost regimens have been safe in over 30
clinical studies in more than 800 patients and healthy volunteers.


Oxxon has built a strong intellectual property estate around the Hi-8(R)
PrimeBoost platform, vectors, antigens and products, which includes rights to 23
patent families resulting in over 100 issued patents or patent applications. The
Hi-8(R) PrimeBoost platform has broad potential applications in preventative
vaccines as well as therapeutic products.


Oxxon was founded in 1999 by a team of experts in immunology from Oxford
University: Professor Adrian Hill, Wellcome Trust Principal Research Fellow and
Director, The Jenner Institute, University of Oxford; Professor Andrew
McMichael, Director of the Weatherall Institute of Molecular Medicine at the
University of Oxford; Professor Geoffrey Smith, Wellcome Trust Principal
Research Fellow, Imperial School of Medicine, and; Dr Joerg Schneider, Vice
President of Research at Oxxon Therapeutics. Investors include MVM Life Science
Partners (UK), Quester (UK), NIF Ventures (Japan) and East Hill Management
(USA).


Further information is available at www.oxti.com


3. Oxxon's Hi-8(R) MEL product candidate

Oxxon's lead product candidate is Hi-8(R) MEL for the treatment of advanced
(stage III/IV) melanoma. Hi-8(R) MEL encodes seven epitopes derived from five
melanoma antigens delivered by a plasmid DNA prime followed by a recombinant
vaccinia virus (MVA) boost. Oxxon has completed a Phase II dose-selection study
of Hi-8(R) MEL product in 41 patients with non-resectable, HLA-A2 positive,
stage III/IV melanoma. Hi-8TM MEL was well tolerated at all doses. Immunological
responses were seen in 91% of patients receiving the highest dose. Eight
patients showed tumour responses (one patient showed a partial response and
seven showed disease stabilisation) for more than 6 months. All but one of the
tumour responses had associated immune responses. Median time to progression was
16 weeks for immune responders and eight weeks for non responders (p<0.05).
After 24 months follow-up, median survival was 100 weeks for immune responders
versus 37 weeks for non-responders (p<0.001) and 42 weeks for a group of control
patients that received standard therapy.


4. Melanoma

Malignant melanoma is the most serious form of skin cancer with a median
survival of less than one year for Stage IV disease and less than five years for
Stage III disease. There are over 15,000 new HLA-A2 positive cases annually in
the developed world and the total treatment market is forecast to be in excess
of US$775 million by 2010 (Datamonitor). Melanoma is increasing in incidence by
more than 4% per year and its prevalence has doubled in the last 20 years.
Existing treatments for stage III/IV metastatic melanoma offer limited efficacy
and often have serious side-effects.



                      This information is provided by RNS
            The company news service from the London Stock Exchange